About Vivex Biomedical
Vivex Biomedical is a Healthcare company based in Marietta (United States) founded in 2012. Provider of tissue matrix, allografts other biogenic materials to treat orthopaedic, spine, wound and soft tissue injuries. Vivex Biomedical has raised $20.49 million across 4 funding rounds from investors including Heritage Bank of Commerce. The company has 177 employees. Vivex Biomedical offers products and services including Amniotic Membrane Allografts, DBM Putty, DBM Sponge, and DBM Fibers. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Regenerative Medicine and Diversified. Its competitors include Tenaya Therapeutics, Athira Pharma and Ensoma; 3 of its 3 listed competitors have raised funding.
Company details
Vivex Biomedical was founded in 2012 in Marietta, United States, within the biomedical sector. Biogenic materials are developed to address therapeutic needs in spine, orthopaedics, dental care, wound management, and responsive implants. Products including tissue matrices and allografts are offered for clinical procedures in these areas. Operations focus on providing biomaterials for injury treatments across orthopaedic and soft tissue applications.
- Annual Revenue$376.83 K (USD)-7as on Dec 31, 2023
- Net Profit$73.39 K (USD)1741as on Dec 31, 2023
- Total Equity Funding$20.49M (USD)
in 4 rounds
- Latest Funding Round$6.28M (USD), Series A
May 2017
- Investors
- Employee Count177
Products & Services of Vivex Biomedical
Vivex Biomedical offers a comprehensive portfolio of products and services, including Amniotic Membrane Allografts, DBM Putty, DBM Sponge, and DBM Fibers.
Allografts for supporting surgical wound treatment in medicine
Bone graft substitute for orthopedic and fusion therapies
Cancellous material for bone repair applications
Fibers used in musculoskeletal injury treatments
Funding Insights of Vivex Biomedical
Vivex Biomedical has successfully raised a total of $20.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $6.28 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.49M
- Total Rounds 4
- Last Round Series A — $6.28M
- First Round $7.6M
(Sep 2013)
- Investors Count 1
All 4 funding rounds of Vivex Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $6.28M | Series A | – | – | – |
| Apr 2017 | $9M | Debt – Conventional | – | – | |
| Jan 2016 | $6.61M | Series A | – | – | – |
| Sep 2013 | $7.6M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Vivex Biomedical
Vivex Biomedical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Heritage Bank of Commerce.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Heritage Bank of Commerce is engaged in providing banking services. | 1994 | heritagebankofcommerce.bank | San Jose, United States |
Investor details for Vivex Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vivex Biomedical
78 people are tracked at Vivex Biomedical (26 in leadership, 8 in board & advisors, 44 in team); the tracked headcount is 177.
| Name | Role | Group |
|---|---|---|
Jeffery Acuff | VP Sales | Leadership |
Laura Trivette | VP, Health Policy & Reimbursement | Leadership |
Courtney Burke | Director Of Executive Accounts- Interventional Spine | Leadership |
Dba Lydia Enriquez M.s., C.p.p. | Vice President Human Resources | Leadership |
Nathaniel Stewart | Director | Leadership |
Jennifer Ardila | Director Of Quality Assurance | Leadership |
Erin Chance | Assistant General Counsel And Chief Compliance Officer | Leadership |
Brian Fromhold | Senior Vice President Finance | Leadership |
Hanna Kaliada | Director Of Research And Development - Operations | Leadership |
Renaud Sicard | Research Director | Leadership |
Laurie Agle | Senior Director Quality & Regulatory Affairs | Leadership |
Drew Lindemann | Area Vice President | Leadership |
H. Thomas Temple | Medical Director | Leadership |
Holly Tally | Vice President | Leadership |
Kassandra Joselin | Human Resources Business Partner | Leadership |
Brittany Hinkley | Director Of Operations | Leadership |
Reinaldo Pascual | Co-President & General Counsel | Leadership |
Timothy Ganey | Chief Technology Officer | Leadership |
Bryan Parks | Director Of IT | Leadership |
Johnson Williams | Area Vice President Of Sales- East | Leadership |
58 more people are available in the full profile.
Complete people profiles for Vivex Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vivex Biomedical
3 dated milestones of Vivex Biomedical across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Vivex Biomedical is founded.
- Funding First funding round of $7.6M.
- Funding Latest funding round, Series A, of $6.3M.
Competitors of Vivex Biomedical
Vivex Biomedical has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Athira Pharma and Ensoma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| athira.com | 2011 | Seattle, United States | $121.04M | 62 | Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool |
Detailed competitors of Vivex Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vivex Biomedical
The website of Vivex Biomedical (vivex.com) receives about 7.2K visits a month.
- Monthly visits7.2K
▲ 134.4% vs previous month
Websites whose visitors overlap most with Vivex Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| woundreference.com | 100% | 15.7K | #1,476,557 | View details | |
| kerecis.com | 98% | 26.1K | #1,192,327 | View details | |
| amendia.com | 97% | View details | |||
| biopharmguy.com | 34% | #377,294 | View details | ||
extremitycare.com | extremitycare.com | 28% | #6,393,061 | – |
Top companies in Cell Therapy
3 companies that operate in the same segment as Vivex Biomedical (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vivex Biomedical
Complete news archive for Vivex Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivex Biomedical
Vivex Biomedical was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Vivex Biomedical is headquartered in Marietta, United States. It is registered at Marietta, Georgia, United States.
Vivex Biomedical is a funded company, having raised a total of $20.49M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7.6M, raised on Sep 2013.
Vivex Biomedical has 177 employees.
Annual revenue of Vivex Biomedical is $376.83K as on Dec 31, 2023.
Vivex Biomedical was founded in 2012 in Marietta, United States, within the biomedical sector. Biogenic materials are developed to address therapeutic needs in spine, orthopaedics, dental care, wound management, and responsive implants. Products including tissue matrices and allografts are offered for clinical procedures in these areas. Operations focus on providing biomaterials for injury treatments across orthopaedic and soft tissue applications.
Vivex Biomedical's top competitors include Tenaya Therapeutics, Athira Pharma and Ensoma.
Vivex Biomedical offers Amniotic Membrane Allografts, DBM Putty, DBM Sponge, and DBM Fibers.
Vivex Biomedical has 1 investor. Key investors include Heritage Bank of Commerce.